BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 28923561)

  • 21. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
    Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
    Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function.
    Basal S; Wambi C; Acikel C; Gupta M; Badani K
    BJU Int; 2013 Apr; 111(4):658-65. PubMed ID: 23186312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple PDE5Is use as a marker of decreased overall men's health: A real-life study.
    Oreggia D; Ventimiglia E; Capogrosso P; Boeri L; Cazzaniga W; Pederzoli F; Chierigo F; Dehò F; Montorsi F; Salonia A
    PLoS One; 2018; 13(8):e0201601. PubMed ID: 30096166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erectile Dysfunction Medications and Treatment for Cardiometabolic Risk Factors: A Pharmacoepidemiologic Study.
    Skeldon SC; Cheng L; Morgan SG; Detsky AS; Goldenberg SL; Law MR
    J Sex Med; 2017 Dec; 14(12):1597-1605. PubMed ID: 29198514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.
    Hong JH; Kwon YS; Kim IY
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):183-192. PubMed ID: 27690667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature.
    Azzouni F; Abu samra K
    J Sex Med; 2011 Oct; 8(10):2894-903. PubMed ID: 21771280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis.
    Corona G; Rastrelli G; Burri A; Jannini EA; Maggi M
    Expert Opin Drug Saf; 2016; 15(2):237-47. PubMed ID: 26646748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors.
    Jannini EA; DeRogatis LR; Chung E; Brock GB
    J Sex Med; 2012 Jan; 9(1):26-33. PubMed ID: 22221307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
    Cui Y; Liu X; Shi L; Gao Z
    Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and satisfaction rates of oral PDE5is in the treatment of erectile dysfunction secondary to spinal cord injury: a review of literature.
    Rizio N; Tran C; Sorenson M
    J Spinal Cord Med; 2012 Jul; 35(4):219-28. PubMed ID: 22925748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.
    Gur S; Kadowitz PJ; Gokce A; Sikka SC; Lokman U; Hellstrom WJ
    Curr Drug Metab; 2013 Feb; 14(2):265-9. PubMed ID: 23140258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy.
    Pomeranz HD
    Neurol Clin; 2017 Feb; 35(1):17-27. PubMed ID: 27886893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
    El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S
    Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.
    Zucchi A; Costantini E; Scroppo FI; Silvani M; Kopa Z; Illiano E; Petrillo MG; Cari L; Nocentini G
    Andrology; 2019 Nov; 7(6):804-817. PubMed ID: 31350821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphodiesterase-5 inhibitors could be efficacious in the treatment of erectile dysfunction after radiotherapy for prostate cancer: a systematic review and meta-analysis.
    Yang L; Qian S; Liu L; Pu C; Yuan H; Han P; Wei Q
    Urol Int; 2013; 90(3):339-47. PubMed ID: 23221333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of phosphodiesterase 5 inhibitors is not associated with ocular adverse events.
    Belladelli F; Li S; Zhang CA; Muncey W; Del Giudice F; Glover F; Seranio N; Basran S; Fallara G; Montorsi F; Salonia A; Eisenberg ML
    J Sex Med; 2023 Nov; 20(12):1399-1406. PubMed ID: 37861186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
    Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
    Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction.
    Cho MC; Paick JS
    Ther Adv Urol; 2016 Apr; 8(2):100-17. PubMed ID: 27034723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.